Biostasis

AI and Biotech Pioneer Alex Zhavoronkov Commits His Life, Estate to Longevity for All

Retrieved on: 
Tuesday, October 25, 2022
Time, Therapy, Deep learning, Life, Telecommunication, Laboratory, MSU, University of Copenhagen Faculty of Health and Medical Sciences, Longevity, Intelligence, Biotechnology, Buck Institute for Research on Aging, Michigan State University College of Natural Science, Research, PNAS, Ageing, Johns Hopkins University, Artificial intelligence, University, Insilico Medicine, Biomarker, Drug discovery, Forbes, Doctor of Philosophy, Industry, CEO, Palgrave Macmillan, Ill, Climate change, GPU, Copenhagen, Regenerative medicine, Robotics, Biostasis, Hematology, Biophysics, In silico, Pharmaceutical industry, Nature, Science

DUBAI, United Arab Emirates, Oct. 25, 2022 /PRNewswire/ -- Today, the artificial intelligence, biotech and longevity pioneer Alex Zhavoronkov, PhD, has publicly called for the world's most successful founders, altruistic billionaires, and dedicated longevity pioneers to join him in his unorthodox and principled "Longevity Pledge."

Key Points: 
  • Alex Zhavoronkov, PhD, is the founder and Chief Longevity Officer of Deep Longevity, the founder and CEO of Insilico Medicine, and an adjunct professor at the esteemed Buck Institute for Research on Aging.
  • Today, Alex Zhavoronkov formally announced his personal " Longevity Pledge ."
  • "Making productive longevity, or the ability to live a longer, healthier life, is the most altruistic cause you can support," said Alex Zhavoronkov.
  • Learn more about Alex Zhavoronkov and the Longevity Pledge at www.LongevityPledge.org .

AI and Biotech Pioneer Alex Zhavoronkov Commits His Life, Estate to Longevity for All

Retrieved on: 
Tuesday, October 25, 2022
Time, Therapy, Deep learning, Life, Telecommunication, Laboratory, MSU, University of Copenhagen Faculty of Health and Medical Sciences, Longevity, Intelligence, Biotechnology, Buck Institute for Research on Aging, Michigan State University College of Natural Science, Research, PNAS, Ageing, Johns Hopkins University, Artificial intelligence, University, Insilico Medicine, Biomarker, Drug discovery, Forbes, Doctor of Philosophy, Industry, CEO, Palgrave Macmillan, Ill, Climate change, GPU, Copenhagen, Regenerative medicine, Robotics, Biostasis, Hematology, Biophysics, In silico, Pharmaceutical industry, Nature, Science

DUBAI, United Arab Emirates, Oct. 25, 2022 /PRNewswire/ -- Today, the artificial intelligence, biotech and longevity pioneer Alex Zhavoronkov, PhD, has publicly called for the world's most successful founders, altruistic billionaires, and dedicated longevity pioneers to join him in his unorthodox and principled "Longevity Pledge."

Key Points: 
  • Alex Zhavoronkov, PhD, is the founder and Chief Longevity Officer of Deep Longevity, the founder and CEO of Insilico Medicine, and an adjunct professor at the esteemed Buck Institute for Research on Aging.
  • Today, Alex Zhavoronkov formally announced his personal " Longevity Pledge ."
  • "Making productive longevity, or the ability to live a longer, healthier life, is the most altruistic cause you can support," said Alex Zhavoronkov.
  • Learn more about Alex Zhavoronkov and the Longevity Pledge at www.LongevityPledge.org .

Vascular Perfusion Solutions Collaborates with Wyss Institute and U.S. Air Force to Study Compound to Improve Organ Transplant Outcomes

Retrieved on: 
Thursday, April 14, 2022
Wyss Institute, CEO, Travel, Military, Massachusetts Institute of Technology, Research, Medtech, Boston University, Medicine, DARPA, Resuscitation, Biostasis, Injury, Wyss Institute for Biologically Inspired Engineering, Organization, Hospital, GLOBE, Wyss, Perfusion, Tissue, SAN, University of Massachusetts Medical School, University, Solution, Science, Atmosphere of Earth, Heart, Temperature, Tufts University, M.D, Metabolism, Environment, United, Harvard University, US Airways, Massachusetts General Hospital, Oxygen, Beth Israel Deaconess Medical Center, Spaulding Rehabilitation Hospital, Industry, Institute, Therapy, 59th Medical Wing, VPS, Berlin, Medical imaging, Pharmaceutical industry, Design, Engineering, Brigham

We were very excited when the invitation came to partner with the Wyss Institute.

Key Points: 
  • We were very excited when the invitation came to partner with the Wyss Institute.
  • We saw the potential for synergy between the two technologies, and said yes right away, said Mark Muller, J.D., the CEO of VPS.
  • However, this time becomes a significant obstacle when organs must travel long distances from their donors to their recipients.
  • Vascular Perfusion Solutions, Inc. is a development and early-stage company, formed for the purpose of commercializing new, unique, and innovative oxygenated perfusion preservation and resuscitation solutions for the bodys limbs, organs, and other vascularized tissue.

Biostasis Research Institute Launches to Enable Human "Organ Banks" Through the Cryogenic Storage of Donor Organs for Transplantation

Retrieved on: 
Wednesday, April 21, 2021
Branches of biology, Organ transplantation, Organ donation, Organ, Biostasis, Life sciences

Yet ironically, donor infant organs are discarded at a higher rate than adults because a suitable recipient can be difficult to find nearby.

Key Points: 
  • Yet ironically, donor infant organs are discarded at a higher rate than adults because a suitable recipient can be difficult to find nearby.
  • Today sections of human brain tissue can be donated and studied in the laboratory while maintaining essential functions such as signaling between neurons.
  • The launch of the Biostasis Research Institute supports our ability to fulfill that commitment.
  • "\n"By funding biostasis research, we are investing in the future of organ donation and transplantation.